Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225-labeled daratumumab
- Development stage
- Preclinical
- Lead developer
- Actinium Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Actinium-225-labeled daratumumab is an experimental antibody radiation-conjugate (ARC) being developed by Actinium Pharmaceuticals as part of its AWE (Actinium Warhead Enabling) Technology Platform. This radiopharmaceutical combines the monoclonal antibody daratumumab, which targets the CD38 antigen, with the potent alpha-particle emitting radioisotope actinium-225. CD38 is a glycoprotein highly expressed on the surface of multiple myeloma cells and certain lymphoma cells, making it an effective target for directed therapy. By delivering high-energy alpha radiation directly to the tumor cells, the conjugate induces lethal double-stranded DNA breaks, significantly enhancing the cytotoxic effect compared to the unlabeled antibody while preserving the antibody's targeting specificity and Fc-mediated effector functions. The compound is currently in preclinical development for the treatment of multiple myeloma and lymphoma.
- Other names
- 225Ac-daratumumabAc-225-daratumumabAc225-daratumumabAc 225-daratumumabactinium-225 daratumumabactinium225 daratumumabactinium 225 daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on actinium-225-labeled daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225-labeled daratumumab.